MacroGenics Inc ((MGNX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MacroGenics Inc is currently conducting a Phase 1 clinical study titled ‘A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies.’ The primary objective of this study is to evaluate the safety, tolerability, and preliminary anti-cancer effects of MGD024 in patients whose blood cancers have not responded to standard therapies or have relapsed. This study is significant as it explores a novel treatment option for challenging hematologic conditions.
The intervention being tested is MGD024, a CD123 x CD3 bispecific DART molecule. This drug is designed to target leukemic cells expressing CD123 for elimination by CD3-expressing T lymphocytes, aiming to provide a new therapeutic avenue for patients with certain blood cancers.
The study is interventional with a sequential intervention model and no masking, focusing primarily on treatment. Participants receive escalating doses of MGD024 based on the safety and tolerability of previous doses, in cycles of 28 days for up to 12 cycles.
The study began on May 2, 2022, with a primary completion date yet to be announced. The estimated study completion date is June 2, 2025, with the last update submitted on the same date. These timelines are crucial for tracking the study’s progress and assessing its potential impact on treatment options.
This study update could influence MacroGenics’ stock performance positively if the results show promise, as it would enhance the company’s portfolio in the competitive field of hematologic malignancies. Investors may view this as a strategic move to capture market share in a niche yet significant segment of cancer treatment.
The study is ongoing, with further details available on the ClinicalTrials portal.